GHP Healthcare & Pharmaceutical Awards 2018

GHP / 2018 Healthcare & Pharmaceutical Awards 7 g Best Clinical Trial Management Firm - Eastern Europe Company: Accell Clinical Research Contact: Svetlana Kazanskaya Phone: +7 (812) 332 1420 Clinical Operations Headquarters: Bolshoy Sampsoniyevskiy pr., 28/D, Suite 317.1, St. Petersburg, 194044, Russia Contractual & Legal Office: 101 E. Culpeper St, Ste. 102, Culpeper, VA 22701, USA Website: accept Russian and Eastern European data. Moreover, it is a fact that most clinical trials within Accell’s region tend to be more cost and time efficient.” Specifically, in the healthcare and pharmaceutical space the firm is constantly expanding its services and has recently redefined itself in a very particular niche which Svetlana is keen to showcase. “Recently, Accell has launched its new brand ‘Accell Oncology’ to highlight our primary focus on oncology clinical trials. At the moment, Accell Oncology is the only oncology-specialized clinical research organization in Eastern Europe. This is dictated by Accell’s excessive experience, both of company and employees alike. We meticulously select best professionals in the industry to maintain an academic level of expertise in our company. From co-founders with substantial oncology backgrounds, to having 80% of clinical staff with Medical Doctor degrees, Accell Oncology offers an unparalleled level of support to oncology studies. The clinical sites under our management have been inspected both by the EMA and by countries’ Regulatory Authorities. Our strong history of audits confirms our commitment to quality work with 100% of Sponsor-initiated audits and inspections resulting in no major findings. “Since its launch, Accell Oncology has supported global cancer research by facilitating clinical trials in Eastern Europe, former CIS countries, Russia and Ukraine. With a deep connection to the oncology sector on a professional and personal levels, we make a commitment to helping find a cure. ESMO reports that treatments for advanced cancer are often unavailable or available only at substantial out of pocket cost in many Eastern European countries, compared to Western Europe. We help bridge the gap by bringing exploratory treatments available in oncology clinical trials to patients and to investigative sites.” Oncology will remain a core focus for Accell as it looks towards a bright future, as Svetlana is excited to conclude. “Looking ahead, Accell’s ongoing focus will remain on Oncology. Cancer is one of the leading causes of mortality worldwide, and the number of new cases is expected to rise by about 70% over the next twenty years. Globally, almost one in every six deaths is due to cancer. These numbers cannot leave us indifferent to a problem of global significance.”